On December 4, 2025, in Shelton, Connecticut, Intensity Therapeutics, Inc. (Nasdaq: INTS) announced its focus on developing unique cancer treatments through non-covalent, drug-conjugation technology. This late-stage clinical biotechnology company is dedicated to pioneering proprietary therapies.
